Variable All (n=115,238) Baloxavir (n=49,872) Neuraminidase inhibitors (n=65,524)
Demographics
Age, median (interquartile range), y
10 (8–13)
11 (9–13)
10 (8–12)
Male sex, N (%)
61,396 (53.3)
26,724 (53.6)
34,763 (53.1)
Comorbidity, N (%)
Asthma/chronic lung disease
24,638 (21.4)
10,797 (21.7)
13,879 (21.1)
Metabolic/endocrine disorder
2,308 (2.0)
954 (1.9)
1,357 (2.1)
Neurological condition
2,553 (2.2)
1,055 (2.1)
1,502 (2.3)
Heart disease
1,990 (1.7)
816 (1.6)
1,178 (1.8)
Blood disease
2,477 (2.1)
1,022 (2.0)
1,458 (2.2)
Any of the above
30,503 (26.4)
13,336 (26.7)
17,211 (26.3)
Outcome, N (%)
Composite
7,945 (6.9)
3,451 (6.9)
4,474 (6.8)
Hospitalization
17 (0.01)
6 (0.01)
11 (0.02)
Laboratory test
6,671 (5.8)
2,876 (5.8)
3,810 (5.8)
Imaging
1,741 (1.5)
787 (1.4)
958 (1.5)
Antibiotics use
3,490 (3.0)
1,488 (3.1)
2,008 (3.1)
Return visit§ 54,724 (47.2) 23,688 (47.3) 31,036 (47.4)